FURAZIDINE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C10H8N4O5
Molecular Weight	264.1943
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	2
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[O-][N+](=O)C1=CC=C(O1)\C=C\C=N\N2CC(=O)NC2=O

InChI

InChIKey=DECBQELQORZLLP-UAIOPKHMSA-N

InChI=1S/C10H8N4O5/c15-8-6-13(10(16)12-8)11-5-1-2-7-3-4-9(19-7)14(17)18/h1-5H,6H2,(H,12,15,16)/b2-1+,11-5+

HIDE SMILES / InChI

Description
Sources: https://www.ukessays.com/essays/sciences/furagin-forced-degradation-studies.php | http://en.medicalmed.de/furagin.php.htm | http://en.medicine-cure.com/ovr3_furamag.htm

Furagin (Furazidine) is a nitrofuran derivative, acting as an antibacterial medicine with bacteriostatic action. It is active against both gram-positive (Staphylococcus epidermidis, Staphylococcus aureus, Staphylococcus faecalis) and gram-negative microorganisms (Enterobacteriaceae – Salmonella, Shygella, Proteus, Klebsiella, Escherichia, Enterobacter, etc.). It is used for the treatment of urinary tract, skin and soft tissues infections.

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
tricarboxylic acid cycle 4 Target ID: GO:0006099 Sources: http://en.medicalmed.de/furagin.php.htm \| http://en.medicine-cure.com/ovr3_furamag.htm \| http://new.dhh.louisiana.gov/assets/oph/Center-PHCH/Center-CH/infectious-epi/VetInfo/VetAntibioResSen/LADDL/AntimicrobialClasses/otherantibiotics/Nitrofurans.pdf	Inhibitor 8297
respiratory chain 3 Target ID: GO:0070469 Sources: http://en.medicalmed.de/furagin.php.htm \| http://en.medicine-cure.com/ovr3_furamag.htm \| http://new.dhh.louisiana.gov/assets/oph/Center-PHCH/Center-CH/infectious-epi/VetInfo/VetAntibioResSen/LADDL/AntimicrobialClasses/otherantibiotics/Nitrofurans.pdf	Inhibitor 8297

Conditions

Condition	Modality	Targets	Highest Phase	Product
Urinary tract infections 205 Sources: http://en.medicalmed.de/furagin.php.htm http://en.medicine-cure.com/ovr3_furamag.htm https://www.rlsnet.ru/tn_index_id_1131.htm	Curative		Approved 8429	Furagin Approved Use Furagin (Furazidine) is indicated for the treatment of urinary tract infections. Topical furagin is used in the treatment of infections of the skin and soft tissues.
Skin and soft tissue infections 33 Sources: http://en.medicalmed.de/furagin.php.htm http://en.medicine-cure.com/ovr3_furamag.htm https://www.rlsnet.ru/tn_index_id_1131.htm	Curative		Approved 8429	Furagin Approved Use Furagin (Furazidine) is indicated for the treatment of urinary tract infections. Topical furagin is used in the treatment of infections of the skin and soft tissues.

PubMed

Title	Date	PubMed
Ciprofloxacin and furagin in acute cystitis: comparison of early immune and microbiological results.	2008 Feb	18060746

Patents

Sample Use Guides

In Vivo Use Guide

Adults: 50-100 mg t.i.d., for 7-14 days. 0.5% or 1% solution for topical applications.

Route of Administration: Other

In Vitro Use Guide

Furagin (Furazidine) is a broad-spectrum antimicrobial agent belonging to the group of nitrofurans. Against the majority of bacteria, the bacteriostatic concentration ranges from 1: 100,000 to 1: 200,000; bactericidal - about 2 times more.

Name

Type

Language

FURAZIDINE

Common Name

English

FURAZIDIN

Common Name

English

1-(((E)-3-(5-NITROFURAN-2-YL)PROP-2-ENYLIDENE)AMINO)IMIDAZOLIDINE-2,4-DIONE

Systematic Name

English

AKRITOIN

Common Name

English

Furazidin [WHO-DD]

Common Name

English

1-((3-(5-NITRO-2-FURYL)ALLYLIDENE)AMINO)HYDANTOIN

Systematic Name

English

FURAZIDIN [MART.]

Common Name

English

FURAGINUM

Brand Name

English

FURAGIN

Brand Name

English

Classification Tree Code System Code

WHO-ATC

J01XE03